New Bladder Cancer Drug Combo: Is It Worth the Cost?

Doctors often use chemotherapy before surgery for bladder cancer. But not everyone can take the standard chemo. This leaves many patients with fewer choices.

A recent study looked at a new drug combo. The drugs are called enfortumab vedotin and pembrolizumab. They are used before and after surgery.

Researchers built a computer model. It compared the new drug combo to surgery alone. The model used real patient data from a major trial.

The trial had over 700 patients. They could not take standard chemo. The follow-up time was about two years.

The study ran from late 2025 to mid-2026. It focused on cost and health benefits.

Results showed the drug combo cost more money. But it also added extra life years for patients.

The cost per quality-adjusted life year was high. This means the treatment is expensive for the health benefit it gives.

Researchers say more data is needed. Long-term results may change the picture.

For now, the combo is an option. But it raises questions about value and access.